查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371921

2030 年生物製药市场预测：按产品类型、应用和地区分類的全球分析

Biopharmaceuticals Market Forecasts to 2030 - Global Analysis By Product Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球生物製药市场规模为 10.4745 亿美元，预计预测期内复合年增长率为 14.4%，到 2030 年将达到 26.8605 亿美元。

生物製药，也称为生物製药或生技药品，是由细胞、有机体和蛋白质等活生物体製成的药物。这些药物是利用生物技术製造的，对现代医疗保健至关重要。此外，生物製药也促进了个人化医疗策略的发展。这些药物有可能针对患者疾病的特定方面，从而可以根据患者的特定遗传特征或疾病亚型製定个体化治疗计划。

根据国际癌症研究机构的数据，2020年约有1,930万人新诊断出癌症，约1,000万人死亡。从 2020 年到 2040 年，癌症患者数量预计将增加 47%。

扩大科学进步

结构生物学、基因编辑和高通量筛选方法等不断发展的科学进步正在改变生物製药的研究和开发。冷冻电子显微镜和尖端成像技术提供的双分子结构的理解有助于药物设计。使用人工智慧和机器学习分析大量资料，以对药物研发做出预测。此外，CRISPR-Cas9 等合成生物学的进步正在使基因治疗和基因编辑细胞疗法成为可能，从而扩大了生物製药的范围。

开发成本过高

生物製药的发展需要在研究、临床前测试和具有挑战性的临床试验方面进行财务投资。除了这些基本成本之外，生物製药公司还必须花费在专门的基础设施上，例如最先进的实验室设备和专门的生产设施，所有这些都会增加开发成本。我是。此外，生物製药开发的长期性和资源集中，单一候选药物的成本往往超过数十亿美元，进一步加剧了财务挑战。

临床试验和个人化医疗的增加

基因组科学和分子诊断的进步使精准医学成为可能，根据患者的遗传特征和特定疾病特征量身定制治疗方法。此策略提高了治疗效果，最大限度地减少副作用并最佳化患者的治疗效果。此外，肿瘤学是个人化医疗特别有前途的领域，因为生物标记主导的治疗正在提高存活率和缓解率。

智慧财产权 (IP) 挑战

生物製药市场的全球性创造了一个复杂的专利、商业机密和专利网络，带来了新的智慧财产权挑战。此外，生物相似药的出现带来了新的法律复杂性，例如专利纠纷和专利丛林策略，这些策略使用多个专利来涵盖单一产品并提供扩展的市场独占权。

COVID-19 的影响：

COVID-19大流行在许多方面对生物製药行业产生了重大影响。对疫苗和治疗方法的迫切需求加速了研发工作，同时也导致了临床试验的延误、全球供应链的中断以及资源重新集中到与疫情相关的活动上。此外，疫情凸显了疫苗开发、抗病毒疗法和生物製药创新的重要性，导致这些领域的投资增加。它也暴露了供应链的弱点，迫使公司重新考虑分销和製造计划。

预计疫苗领域在预测期内将是最大的产业。

疫苗领域通常占据最大的市场。疫苗可预防多种感染疾病，对公共卫生至关重要。对于当前的威胁（如 COVID-19）和新的威胁（如流感和肝炎），疫苗变得越来越受欢迎。全球对疫苗的需求急剧增加，特别是由于 COVID-19 大流行。然而，由于持续的研发活动，包括创建 mRNA 疫苗等新疫苗平台，疫苗市场对于生物製药行业的扩张和改善公众健康的配合措施仍然至关重要。

预计癌症领域在预测期内年复合成长率最高

生物製药市场年复合成长率最高的预计将出现在肿瘤领域。其主要原因包括全球癌症罹患率上升、标靶治疗和免疫疗法的进步以及精准医疗技术的持续研究。此外，由于针对各种癌症类型的新型生物药品的开发以及联合治疗和生物标记主导治疗的潜力，肿瘤学市场正在经历显着增长。

比例最高的地区：

全球生物製药市场通常占据北美地区，尤其是美国的最大份额。造成这一优势的因素包括强大的製药业、大量的研发支出、发达的医疗保健系统、庞大的患者基础以及支持生物製药开发和商业化的法规环境。此外，北美拥有大量生物製药公司、学术研究中心和生物技术中心，这也有助于提高其市场占有率。

复合年复合成长率最高的地区：

生物製药市场年复合成长率最高的是亚太地区。中等收入人口的成长、医疗保健成本的上升、药品製造能力的提高以及对最先进治疗的需求不断增加只是该行业蓬勃发展的部分原因。对生物製药和疫苗的研发、临床试验以及製造的投资尤其使中国和印度等国家成为生物製药产业的主要企业。此外，该地区的快速成长也得到了政府的支持政策以及与大型製药企业的合作伙伴关係的支持。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球生物製药市场：依产品类型

  • 单株抗体
    • 抗癌单株抗体
    • 发炎单株抗体
  • 干扰素
  • 胰岛素
  • 生长因子和凝血因子
  • 疫苗
    • 重组疫苗
      • 癌症疫苗
      • 疟疾疫苗
      • 伊波拉疫苗
      • 乙型肝炎疫苗
      • 破伤风疫苗
      • 白喉疫苗
      • 霍乱疫苗
    • 常规疫苗
      • 小儿麻痹疫苗
      • 痘疫苗
  • 重组生长因子
    • 促红血球生成素
    • 颗粒细胞增生因子
  • 精製蛋白
    • 白血病抑制因子（LIF）
    • P53蛋白
    • P38蛋白
  • 重组蛋白
    • 血清白蛋白
    • 淀粉样蛋白
    • 防御素
    • 转铁蛋白
  • 合成免疫调节剂
  • 重组激素
    • 重组人生长激素
    • 重组胰岛素
  • 重组酵素
    • 肠激酶
    • 环化酶
    • 胱天蛋白酶
    • 组织蛋白酶
  • 细胞和基因治疗
    • 同种异体产品
    • 自我产品
    • 无细胞产品
  • 合成免疫调节剂
    • 细胞因子
    • 干扰素
    • 白血球介素
  • 其他产品类型

第6章全球生物製药市场：依应用分类

  • 肿瘤学
  • 血液疾病
  • 代谢性疾病
  • 感染疾病
  • 循环系统疾病
  • 神经系统疾病
  • 免疫学
  • 自体免疫疾病
  • 荷尔蒙失调
  • 其他用途

第7章全球生物製药市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第8章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第9章公司简介

  • Merck & Co., Inc.
  • Novartis AG
  • Abbott Laboratories.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Biogen Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Sanofi
  • Bayer AG
  • Allergan plc
  • Johnson & Johnson
  • Amgen Inc.
Product Code: SMRC23978

According to Stratistics MRC, the Global Biopharmaceuticals Market is accounted for $1047.45 million in 2023 and is expected to reach $2686.05 million by 2030 growing at a CAGR of 14.4% during the forecast period. Biopharmaceuticals, also referred to as biologic drugs or biologics, are pharmaceuticals made from living things like cells, organisms, or proteins. These medications are produced using biotechnology techniques and are essential to contemporary healthcare. Moreover, biopharmaceuticals have made it possible to develop personalized medicine strategies. These medications have the potential to target particular molecular aspects of a patient's illness, enabling the development of personalized treatment plans based on the patient's particular genetic profile or disease subtype.

According to the International Agency for Research on Cancer, in the year 2020, around 19.3 million new cases of cancer were diagnosed and around 10 million cancer deaths were recorded. The cancer cases are estimated to grow by 47% from 2020 to 2040.

Market Dynamics:

Driver:

Expanding scientific advances

Biopharmaceutical R&D is being transformed by ongoing scientific advances in structural biology, gene editing, and high-throughput screening methods. Drug design is aided by the understanding of bimolecular structures provided by cryo-electron microscopy and cutting-edge imaging technologies. Massive datasets are analyzed using artificial intelligence and machine learning to make predictions about drug discovery. Additionally, gene therapies and gene-edited cell therapies have been made possible by advances in synthetic biology, such as CRISPR-Cas9, expanding the range of biopharmaceuticals.

Restraint:

Excess development costs

Financial investments in research, preclinical studies, and challenging clinical trials are significant in the development of biopharmaceuticals. In addition to these basic costs, biopharmaceutical businesses also have to spend money on specialized infrastructure, such as state-of-the-art lab tools and specialized manufacturing facilities, all of which drive up development costs. Furthermore, the lengthy and resource-intensive nature of biopharmaceutical development, where costs frequently exceed billions of dollars for a single drug candidate, further exacerbates financial difficulties.

Opportunity:

Increasing clinical trials and personalized medicine

Precision medicine, which tailors treatments to a person's genetic profile and particular disease characteristics, is being made possible by developments in genomics and molecular diagnostics. With this strategy, treatment effectiveness is improved, side effects are minimized, and patient outcomes are optimized. Moreover, oncology is a field where personalized medicine holds particular promise because biomarker-driven therapies are increasing survival and response rates.

Threat:

Challenges to intellectual property (IP)

A complex web of patents, trade secrets, and patent thickets must be negotiated by businesses due to the global nature of the biopharmaceutical market, which presents additional IP challenges. Additionally, the emergence of biosimilars brings with it new legal complexities, such as patent disputes and patent thicket strategies, where multiple patents are used to cover a single product and provide for extended market exclusivity.

COVID-19 Impact:

The COVID-19 pandemic affected the biopharmaceutical industry significantly and in a variety of ways. In addition to delaying clinical trials, disrupting global supply chains, and refocusing resources on pandemic-related activities, the urgent need for vaccines and treatments accelerated research and development efforts. Moreover, the pandemic highlighted the significance of vaccine development, antiviral therapies, and biopharmaceutical innovation, leading to increased investments in these fields. It also exposed weaknesses in supply chains, forcing businesses to reconsider their distribution and manufacturing plans.

The Vaccines segment is expected to be the largest during the forecast period

The vaccines segment typically holds the largest share of the market. A wide range of infectious diseases are prevented by vaccines, which are essential to public health. They have become more well-known for both current threats like COVID-19 and emerging ones like influenza and hepatitis. The global demand for vaccines has increased dramatically as a result of the COVID-19 pandemic in particular. However, the vaccine market is still essential to the expansion of the biopharmaceutical industry and efforts to improve public health due to ongoing research and development activities, including the creation of new vaccine platforms like mRNA vaccines.

The Oncology segment is expected to have the highest CAGR during the forecast period

The biopharmaceutical market's highest CAGR is anticipated in the oncology segment. This is mainly because of a number of things, such as the rising incidence of cancer globally, developments in targeted and immunotherapeutic therapies, and ongoing work on precision medicine methods. Moreover, the oncology market has experienced significant growth as a result of the creation of novel biopharmaceuticals for various cancer types as well as the potential for combination therapies and biomarker-driven treatments.

Region with largest share:

The global biopharmaceutical market typically holds the largest share in the North American region, in particular the United States. A strong pharmaceutical industry, significant R&D expenditures, a developed healthcare system, a sizable patient base, and a supportive regulatory environment for the development and commercialization of biopharmaceuticals were all cited as contributing factors to this dominance. Additionally, its sizeable market share was influenced by the fact that North America is home to a large number of biopharmaceutical businesses, academic research centers, and biotechnology hubs.

Region with highest CAGR:

The biopharmaceutical market was growing at the highest CAGR in the Asia-Pacific region. A rising middle-class population, rising healthcare costs, growing pharmaceutical manufacturing capacity, and rising demand for cutting-edge treatments are just a few of the reasons for this industry's rapid growth. Due to their investments in R&D, clinical trials, and the production of biologic drugs and vaccines, nations like China and India in particular were emerging as major players in the biopharmaceutical industry. Moreover, the region's rapid growth was also aided by supportive government policies and partnerships with major pharmaceutical corporations.

Key players in the market:

Some of the key players in Biopharmaceuticals market include: Merck & Co., Inc. , Novartis AG, Abbott Laboratories., Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Biogen Inc. , AbbVie Inc., Pfizer Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Sanofi, Bayer AG, Allergan plc , Johnson & Johnson and Amgen Inc.

Key Developments:

In October 2023, Sanofi has reached an agreement to develop and commercialize an experimental vaccine candidate for extra intestinal pathogenic E. coli developed by Janssen Pharmaceuticals. Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m upfront, followed by development and commercial milestones. Both parties will co-fund current and future research and development costs. Extra intestinal pathogenic E. coli is a common gram-negative bacteria pathogen in humans and a leading cause of sepsis, particularly in older adults.

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's Library of Libraries, a collection of synthetic antibody libraries that harnesses innovative structural and develops ability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of antibody discovery programs across indications and focus areas.

In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical. Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered:

  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Growth and Coagulation Factor
  • Vaccines
  • Recombinant Growth Factors
  • Purified Proteins
  • Recombinant Proteins
  • Synthetic Immunomodulators
  • Recombinant Hormones
  • Recombinant Enzymes
  • Cell and Gene Therapies
  • Synthetic Immunomodulators
  • Other Product Types

Applications Covered:

  • Oncology
  • Blood disorder
  • Metabolic disease
  • Infectious disease
  • Cardiovascular disease
  • Neurological disease
  • Immunology
  • Autoimmune Disorders
  • Hormonal Disorders
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biopharmaceuticals Market, By Product Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
    • 5.2.1 Anti-cancer Monoclonal Antibodies
    • 5.2.2 Anti-inflammatory Monoclonal Antibodies
  • 5.3 Interferon
  • 5.4 Insulin
  • 5.5 Growth and Coagulation Factor
  • 5.6 Vaccines
    • 5.6.1 Recombinant Vaccines
      • 5.6.1.1 Cancer Vaccine
      • 5.6.1.2 Malaria Vaccine
      • 5.6.1.3 Ebola Vaccine
      • 5.6.1.4 Hepatitis-B Vaccine
      • 5.6.1.5 Tetanus Vaccine
      • 5.6.1.6 Diphtheria Vaccine
      • 5.6.1.7 Cholera Vaccine
    • 5.6.2 Conventional Vaccines
      • 5.6.2.1 Polio Vaccine
      • 5.6.2.2 Pox Vaccine
  • 5.7 Recombinant Growth Factors
    • 5.7.1 Erythropoietin
    • 5.7.2 Granulocyte Colony Stimulating Factor
  • 5.8 Purified Proteins
    • 5.8.1 Leukemia Inhibitory Factor (LIF)
    • 5.8.2 P53 Protein
    • 5.8.3 P38 Protein
  • 5.9 Recombinant Proteins
    • 5.9.1 Serum Albumin
    • 5.9.2 Amyloid Protein
    • 5.9.3 Defensin
    • 5.9.4 Transferrin
  • 5.10 Synthetic Immunomodulators
  • 5.11 Recombinant Hormones
    • 5.11.1 Recombinant Human Growth Hormones
    • 5.11.2 Recombinant Insulin
  • 5.12 Recombinant Enzymes
    • 5.12.1 Enterokinase
    • 5.12.2 Cyclase
    • 5.12.3 Caspase
    • 5.12.4 Cathepsin
  • 5.13 Cell and Gene Therapies
    • 5.13.1 Allogenic Products
    • 5.13.2 Autologous Products
    • 5.13.3 Acellular Products
  • 5.14 Synthetic Immunomodulators
    • 5.14.1 Cytokines
    • 5.14.2 Interferons
    • 5.14.3 Interleukins
  • 5.15 Other Product Types

6 Global Biopharmaceuticals Market, By Application

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Blood disorder
  • 6.4 Metabolic disease
  • 6.5 Infectious disease
  • 6.6 Cardiovascular disease
  • 6.7 Neurological disease
  • 6.8 Immunology
  • 6.9 Autoimmune Disorders
  • 6.10 Hormonal Disorders
  • 6.11 Other Applications

7 Global Biopharmaceuticals Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Merck & Co., Inc.
  • 9.2 Novartis AG
  • 9.3 Abbott Laboratories.
  • 9.4 Novo Nordisk A/S
  • 9.5 Eli Lilly and Company
  • 9.6 AstraZeneca PLC
  • 9.7 Bristol-Myers Squibb Company
  • 9.8 Biogen Inc.
  • 9.9 AbbVie Inc.
  • 9.10 Pfizer Inc.
  • 9.11 Bausch Health Companies Inc.
  • 9.12 F. Hoffmann-La Roche AG
  • 9.13 Sanofi
  • 9.14 Bayer AG
  • 9.15 Allergan plc
  • 9.16 Johnson & Johnson
  • 9.17 Amgen Inc.

List of Tables

  • Table 1 Global Biopharmaceuticals Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biopharmaceuticals Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Biopharmaceuticals Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Biopharmaceuticals Market Outlook, By Anti-cancer Monoclonal Antibodies (2021-2030) ($MN)
  • Table 5 Global Biopharmaceuticals Market Outlook, By Anti-inflammatory Monoclonal Antibodies (2021-2030) ($MN)
  • Table 6 Global Biopharmaceuticals Market Outlook, By Interferon (2021-2030) ($MN)
  • Table 7 Global Biopharmaceuticals Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 8 Global Biopharmaceuticals Market Outlook, By Growth and Coagulation Factor (2021-2030) ($MN)
  • Table 9 Global Biopharmaceuticals Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 10 Global Biopharmaceuticals Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 11 Global Biopharmaceuticals Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
  • Table 12 Global Biopharmaceuticals Market Outlook, By Recombinant Growth Factors (2021-2030) ($MN)
  • Table 13 Global Biopharmaceuticals Market Outlook, By Erythropoietin (2021-2030) ($MN)
  • Table 14 Global Biopharmaceuticals Market Outlook, By Granulocyte Colony Stimulating Factor (2021-2030) ($MN)
  • Table 15 Global Biopharmaceuticals Market Outlook, By Purified Proteins (2021-2030) ($MN)
  • Table 16 Global Biopharmaceuticals Market Outlook, By Leukemia Inhibitory Factor (LIF) (2021-2030) ($MN)
  • Table 17 Global Biopharmaceuticals Market Outlook, By P53 Protein (2021-2030) ($MN)
  • Table 18 Global Biopharmaceuticals Market Outlook, By P38 Protein (2021-2030) ($MN)
  • Table 19 Global Biopharmaceuticals Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
  • Table 20 Global Biopharmaceuticals Market Outlook, By Serum Albumin (2021-2030) ($MN)
  • Table 21 Global Biopharmaceuticals Market Outlook, By Amyloid Protein (2021-2030) ($MN)
  • Table 22 Global Biopharmaceuticals Market Outlook, By Defensin (2021-2030) ($MN)
  • Table 23 Global Biopharmaceuticals Market Outlook, By Transferrin (2021-2030) ($MN)
  • Table 24 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
  • Table 25 Global Biopharmaceuticals Market Outlook, By Recombinant Hormones (2021-2030) ($MN)
  • Table 26 Global Biopharmaceuticals Market Outlook, By Recombinant Human Growth Hormones (2021-2030) ($MN)
  • Table 27 Global Biopharmaceuticals Market Outlook, By Recombinant Insulin (2021-2030) ($MN)
  • Table 28 Global Biopharmaceuticals Market Outlook, By Recombinant Enzymes (2021-2030) ($MN)
  • Table 29 Global Biopharmaceuticals Market Outlook, By Enterokinase (2021-2030) ($MN)
  • Table 30 Global Biopharmaceuticals Market Outlook, By Cyclase (2021-2030) ($MN)
  • Table 31 Global Biopharmaceuticals Market Outlook, By Caspase (2021-2030) ($MN)
  • Table 32 Global Biopharmaceuticals Market Outlook, By Cathepsin (2021-2030) ($MN)
  • Table 33 Global Biopharmaceuticals Market Outlook, By Cell and Gene Therapies (2021-2030) ($MN)
  • Table 34 Global Biopharmaceuticals Market Outlook, By Allogenic Products (2021-2030) ($MN)
  • Table 35 Global Biopharmaceuticals Market Outlook, By Autologous Products (2021-2030) ($MN)
  • Table 36 Global Biopharmaceuticals Market Outlook, By Acellular Products (2021-2030) ($MN)
  • Table 37 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
  • Table 38 Global Biopharmaceuticals Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 39 Global Biopharmaceuticals Market Outlook, By Interferons (2021-2030) ($MN)
  • Table 40 Global Biopharmaceuticals Market Outlook, By Interleukins (2021-2030) ($MN)
  • Table 41 Global Biopharmaceuticals Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 42 Global Biopharmaceuticals Market Outlook, By Application (2021-2030) ($MN)
  • Table 43 Global Biopharmaceuticals Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 44 Global Biopharmaceuticals Market Outlook, By Blood disorder (2021-2030) ($MN)
  • Table 45 Global Biopharmaceuticals Market Outlook, By Metabolic disease (2021-2030) ($MN)
  • Table 46 Global Biopharmaceuticals Market Outlook, By Infectious disease (2021-2030) ($MN)
  • Table 47 Global Biopharmaceuticals Market Outlook, By Cardiovascular disease (2021-2030) ($MN)
  • Table 48 Global Biopharmaceuticals Market Outlook, By Neurological disease (2021-2030) ($MN)
  • Table 49 Global Biopharmaceuticals Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 50 Global Biopharmaceuticals Market Outlook, By Autoimmune Disorders (2021-2030) ($MN)
  • Table 51 Global Biopharmaceuticals Market Outlook, By Hormonal Disorders (2021-2030) ($MN)
  • Table 52 Global Biopharmaceuticals Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.